| Document |
Document Title |
|
WO/2021/027744A1 |
Provided in the present invention are a 3-hydroxy-5-pregnane-20-one derivative as shown in formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the derivative or the pharmaceutically accept...
|
|
WO/2021/023213A1 |
The present invention relates to a steroid derivative regulator, in particular to a compound of formula (I), a salt and crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effect...
|
|
WO/2021/012671A1 |
Disclosed is a highly efficient preparation method for progesterone with low pollution, pertaining to the technical field of preparation and processing of steroid hormone drugs. The method uses 21-hydroxy-20-methylpregna-4-en-3-one as a ...
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/245641A1 |
The present disclosure relates to novel ester forms of medroxyprogesterone, process for their preparation and pharmaceutical compositions comprising the same. The present disclosure also relates to use of the novel ester forms in hormona...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/210116A1 |
The invention provides steroid compounds with altered pharmacological properties and methods of using the compounds to treat a condition in a subject.
|
|
WO/2020/187965A1 |
The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.
|
|
WO/2020/185710A1 |
The present disclosure relates to methods of alleviating a symptom of, treating, or preventing a sleep disorder by administering a neurosteroid GABAA positive allosteric modulator or pharmaceutically acceptable salt thereof to a subject ...
|
|
WO/2020/181395A1 |
The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase i...
|
|
WO/2020/135352A1 |
Disclosed is a method for preparing a progesterone particulate, especially a crystal or powder. The method comprises: step 1, dissolving progesterone in a solvent to provide a progesterone solution; step 2, pumping the progesterone solut...
|
|
WO/2020/132504A1 |
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...
|
|
WO/2020/124094A1 |
The invention relates to methods of treating depression with Compound 1 or pharmaceutically acceptable salts thereof. The present disclosure, among other things, provides methods of treating depression by administering a therapeutically ...
|
|
WO/2020/118142A1 |
Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and...
|
|
WO/2020/083839A1 |
The present invention relates to a new process for the synthesis of 3a-hydroxy-5a-pregnan-20-one, commonly known as brexanolone, wherein the corresponding cyclic 20-ketal or cyclic 20-thioketal compound of formula (IV) is deprotected wit...
|
|
WO/2020/082065A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...
|
|
WO/2020/077255A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...
|
|
WO/2020/006596A1 |
Disclosed are neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same. The invention provides scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadol...
|
|
WO/2020/000080A1 |
A system for preventing and treating the bends and blockages of blood flow, such as heart attacks and ischemic strokes. The system comprises the application of ultrasound, with cooling of the affected body area, to break up and reduce in...
|
|
WO/2019/211668A3 |
The present invention contemplates novel neurosteroid derivative compounds, such as derivatives of ganaxolone and allopregnanolone, having improved solubility and bioavailability. The novel neurosteroid derivative compounds are character...
|
|
WO/2019/211668A2 |
The present invention contemplates novel neurosteroid derivative compounds, such as derivatives of ganaxolone and allopregnanolone, having improved solubility and bioavailability. The novel neurosteroid derivative compounds are character...
|
|
WO/2019/154257A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
WO/2019/154247A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...
|
|
WO/2019/128154A1 |
Provided is a method for synthesizing the 17-position side chain of a steroid drug, wherein same is characterized in using compound I as a starting material, and the 17-position side chain is synthesized by nucleophilic, esterification, ...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/113494A1 |
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...
|
|
WO/2018/222701A1 |
The present application relates to methods of treating or preventing a renal disease, disorder, or condition (e.g., age-, diabetes- and/or obesity-related renal disease, disorder, or condition) in a subject in need thereof, comprising ad...
|
|
WO/2018/137260A1 |
Disclosed in the present application is a method for preparing a compound I, which is characterized in being prepared and obtained by reacting starting materials which comprise a compound II, which contains a carbon-carbon double bond, a...
|
|
WO/2018/127601A1 |
The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non- micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols a...
|
|
WO/2018/109508A1 |
The invention relates to the last step of a synthetic process, in which Nomegestrol- acetate of formula (I) is synthesized from 17α-acetoxy-6-methylene-19-norpregn-4-ene-3,20-dione of formula (II) in the presence of Pd/C catalyst and ac...
|
|
WO/2018/103626A1 |
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...
|
|
WO/2018/064649A1 |
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...
|
|
WO/2018/013615A1 |
Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b,R12, R16, R17, R19, and ----- are as define...
|
|
WO/2018/013613A1 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
|
WO/2017/150723A1 |
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...
|
|
WO/2017/004205A1 |
The present invention relates to compounds and methods which may be useful as treatments of diseases.
|
|
WO/2016/209847A1 |
The present invention relates to C-20 steroid compounds, compositions and methods of use thereof to treat, minimize and/or prevent traumatic brain injury (TBI), including severe TBI, moderate TBI and mild TBI, including concussions.
|
|
WO/2016/164763A8 |
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and su...
|
|
WO/2016/164763A1 |
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and su...
|
|
WO/2016/154772A1 |
The present invention relates to a method for preparing 9β,10α-pregnane-4,6-diene-3,20-dione. The preparation method uses 9β,10α-pregnane-5,7-diene-3,20-dione diethyl diacetal (compound A) as a raw material, which is deprotected unde...
|
|
WO/2016/040322A1 |
Described herein are methods of treating tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor;...
|
|
WO/2014/169833A9 |
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplate...
|
|
WO/2015/075693A8 |
The invention relates to a process for the synthesis of (11β,17α)-17-acetoxy-11 - methyl-19-norpregn-4-en-3,20-dione of formula (I) using the compound of formula (II) as starting material as well as the intermediates of the process.
|
|
WO/2015/195962A1 |
Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment...
|
|
WO/2015/180679A1 |
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as def...
|
|
WO/2015/134670A1 |
In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to novel isotoplogues of 3α-hydroxy-3β-methyl-5α-pregnan-20-one (ganaxolone). In accordance with one a...
|
|
WO/2015/092647A1 |
The present invention relates to a new stereoselective process for the synthesis of 17(α)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(α)-17-acetyl-17-hy droxy-estr-4-e...
|
|
WO/2015/075693A1 |
The invention relates to a process for the synthesis of (11 β,17α)-17-acetoxy-11 - inethyl-19-norpregn-4-en-3,20-dione of formula (I) using the compound of formula (II) as starting material as well as the intermediates of the process.
|
|
WO/2015/049637A1 |
The present invention relates to a new process for the synthesis of compounds of formula (I) (wherein the meaning of R is dimethylamino or acetyl group) using the compound of formula (II) (wherein the meaning of R is dimethylamino or 2-m...
|
